Clinical Trial Update: A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension [Phase 3]

View source ↗

Summary

A long-term, open-label Phase 3 safety study of sitaxsentan sodium in pulmonary arterial hypertension was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Sitaxsentan Sodium (sitaxsentan)

Snippet

Sponsor: Pfizer | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2012-04-24